New Leo Pharma-drug gains EU approval
The European Commission has approved a new drug from the Danish company Leo Pharma for the European market.
by Stefan Singh Kailay
50,000 Danes could be looking forward to new treatment to prevent the development of skin cancer after the EU Commission has approved Leo Pharma’s drug Picato for marketing in the EU, the company announces.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Leo Pharma: Approval opens up a huge market
For abonnenter
Leo Pharma: A strategy for each country
For abonnenter
